In the blood, platelets are the smallest cells that play a hemostatic role in the body. The immediate manifestation of thrombocytopenia is easy bleeding, such as bleeding spots and petechiae on the skin, bleeding gums, nosebleeds, and during labor there may be excessive postpartum bleeding or excessive bleeding from cesarean wounds, even affecting the fetus and leading to spontaneous abortion, intrauterine death or intracranial hemorrhage in the newborn. Thrombocytopenia is the most common hematological abnormality during pregnancy. After pregnancy, due to increased blood volume, blood thinning, increased consumption due to blood hypercoagulation and increased collection and utilization of platelets by the placenta, there can be a physiological decrease in platelet count, which usually does not fall below 70×109/L. This is called “thrombocytopenia of pregnancy”. With this level of platelet count, there is usually no bleeding and the pregnancy and delivery can go smoothly and return to normal after delivery. If the platelet count falls below 50×109/L or even 20×109/L, it is likely to be immune thrombocytopenia (ITP). As a result of the body’s immune dysfunction, anti-self platelet antibodies are produced, leading to excessive platelet destruction and a significant shortening of the life span, resulting in a significant decrease in the number of platelets. Most patients have reduced platelets before pregnancy, but they are just asymptomatic and undetected, and aggravated during pregnancy, while some patients present after pregnancy. Doctors will first rule out the possibility of immune thrombocytopenia secondary to viral or bacterial infections (human immunodeficiency virus, hepatitis C virus and Helicobacter pylori, etc.) and autoimmune diseases (such as systemic lupus erythematosus, antiphospholipid antibody syndrome, etc.) based on symptoms and relevant tests. If there is a high suspicion of thrombocytopenia due to serious hematologic disorders, such as acute leukemia or aplastic anemia, the doctor will recommend a bone marrow aspiration. The risk of performing a bone marrow aspiration test during pregnancy is not significant, but to avoid the effects of maternal stress, fear, pain and allergy to local anesthetics on the fetus, a bone marrow aspiration test may not be performed during pregnancy if immune thrombocytopenia is considered. Pregnant women with thrombocytopenia should Wang Wensheng limit activities, avoid trauma, and avoid constipation. Asymptomatic normal pregnant women with platelets >20X109/L do not need treatment until delivery. The mode of delivery is determined by obstetric indications and is not influenced by the platelet count. To reduce the risk of hemorrhage in labor, measures should be taken to achieve a platelet count >50 X109/L for normal vaginal delivery and >50 X109/L for cesarean section, except for epidural anesthesia which requires a platelet count >80 X109/L. Intravenous gammaglobulin can be given 1-2 weeks before delivery or a single platelet transfusion on the day of delivery. Pregnant women with platelet counts <20x109/L need to be treated as soon as possible to raise platelet levels because of the higher risk of severe spontaneous bleeding. Gammaglobulin is safe for the fetus in early pregnancy, but glucocorticoids may increase the risk of fetal malformations in the first trimester. Depending on the severity of the condition, it is necessary to discuss with the doctor whether to continue the pregnancy. Platelets can be transfused to reduce the risk of bleeding if the platelets are << span="">10′109/L or if there is a bleeding tendency, and before delivery, but repeated platelet transfusions producing platelet antibodies will result in ineffective platelet transfusions, so platelet transfusions should not be relied upon during pregnancy. Newborns may be affected by maternal anti-platelet antibodies and therefore platelet counts should be monitored until 2-5 days postpartum after the platelet minimum. Platelets 20′109/L or bleeding should be given with gammaglobulin and platelet transfusions. Other serious diseases that may lead to thrombocytopenia, such as pre-eclampsia, HELLP syndrome, thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), acute fatty liver during pregnancy, and disseminated intravascular coagulation (DIC) are serious maternal life-threatening conditions that require hospitalization and aggressive treatment.